Dr. Chetan Kalal was invited as Faculty to Obesity Masterclass 2026. A comprehensive review of MASLD, liver fibrosis assessment in obese patients, bariatric surgery and the liver, emerging MASH pharmacotherapy (resmetirom, semaglutide), and MASLD-related liver transplant.
Liver cirrhosis is the end stage of chronic liver inflammation and fibrosis. Once cirrhosis is established, the liver architecture is permanently altered — but with the right management, disease progression can be halted, complications prevented, and survival significantly extended. In decompensated cirrhosis, specialist hepatology input determines whether a patient recovers to a compensated state or deteriorates toward liver failure. This article explains cirrhosis, its causes in India, how it is graded, and what specialist treatment in Mumbai involves. What is liver cirrhosis? Cirrhosis is diffuse hepatic fibrosis with nodule formation — the liver’s normal architecture replaced by scar tissue. It is the final common pathway of chronic liver injury regardless of cause. The liver loses its regenerative capacity and its ability to perform key functions: protein synthesis (albumin, clotting factors), detoxification, bile production, and glucose regulation. Compensated cirrhosis: The liver maintains adequate function. Patients may be asymptomatic or mildly symptomatic. Without treatment of the underlying cause, progression to decompensation is inevitable — at a rate of approximately 5–10% per year. Decompensated cirrhosis: The liver can no longer maintain function. Defined by the appearance of: ascites (fluid in abdomen), variceal bleeding (from oesophageal or gastric varices), hepatic encephalopathy (confusion, altered consciousness), or jaundice with coagulopathy. Each decompensation event carries significant mortality and marks a transition point where liver transplant evaluation should begin. Causes of cirrhosis in India Alcohol-related liver disease (ALD) — the leading cause in urban India; cirrhosis develops after 10–15 years of heavy drinking in susceptible individuals Hepatitis B (HBV) — India has an intermediate endemicity of ~3.5%; HBV-related cirrhosis is common, particularly in men over 40 Hepatitis C (HCV) — less prevalent than HBV but increasing; now curable with direct-acting antivirals (DAAs) MASLD/NASH — metabolic-associated steatotic liver disease; the fastest-growing cause of cirrhosis in India, driven by obesity, type 2 diabetes, and metabolic syndrome Autoimmune hepatitis (AIH) — more common in women; treatable with immunosuppression if caught early Wilson’s disease — hereditary copper overload; causes cirrhosis in young patients if untreated Cryptogenic cirrhosis — no identifiable cause after complete workup; often represents burned-out NASH or undetected autoimmune disease Grading cirrhosis — Child-Pugh and MELD Child-Pugh score (A/B/C) assesses five parameters: bilirubin, albumin, INR, ascites, and encephalopathy. Child-Pugh A = compensated; Child-Pugh C = severely decompensated, 1-year survival without transplant approximately 35–45%. MELD score (Model for End-Stage Liver Disease) uses bilirubin, creatinine, and INR to estimate 90-day mortality. MELD ≥15 is the threshold at which liver transplant is considered to offer survival benefit. MELD 3.0 (the updated version incorporating sodium and sex) is now standard in transplant listing. These scores guide treatment intensity and transplant listing decisions — they should be calculated and interpreted by a trained hepatologist, not just generated by an online calculator. Complications of cirrhosis — specialist management Ascites First-line: sodium restriction and diuretics (spironolactone ± furosemide). Refractory ascites (not responding to diuretics): large-volume paracentesis with albumin infusion, TIPS evaluation, or transplant listing. Spontaneous bacterial peritonitis (SBP) — a life-threatening infection of ascitic fluid — requires prompt diagnosis by paracentesis and empirical antibiotics. Secondary prophylaxis with norfloxacin is mandatory after a first SBP episode. Variceal bleeding Medical: terlipressin or somatostatin analogues plus early endoscopy (within 12 hours). Endoscopic: band ligation for oesophageal varices. Secondary prophylaxis: non-selective beta-blockers (propranolol or carvedilol) plus repeated band ligation. TIPS for refractory or early re-bleeding. Failure of TIPS = transplant indication. Hepatic encephalopathy Precipitant identification and treatment (infection, bleeding, electrolyte disturbance, constipation). Lactulose titrated to 2–3 soft stools per day. Rifaximin for recurrent or persistent encephalopathy. Zinc supplementation. Nutritional support — adequate protein (1.2–1.5 g/kg/day) is essential; protein restriction is harmful and outdated. Hepatorenal syndrome (HRS) HRS-AKI: terlipressin + albumin is the treatment of choice (EASL 2018; AASLD). Early diagnosis critical — serum creatinine rise in a cirrhotic patient requires prompt assessment for HRS vs. pre-renal vs. intrinsic renal disease. HRS-CKD: renal function may not recover; transplant is the definitive treatment. Cirrhosis and liver transplant — when to refer Liver transplant evaluation should be initiated — not deferred — when: MELD ≥15 or Child-Pugh C First episode of SBP (indicates significantly impaired immunity and prognosis) Refractory ascites requiring frequent paracentesis Recurrent variceal bleeding despite secondary prophylaxis Hepatic encephalopathy requiring hospitalisation HCC within Milan criteria (transplant is curative in selected patients) In India, LDLT is the dominant modality. A family member or spouse can donate a lobe of their liver. The hepatologist’s role is to evaluate the recipient’s candidacy, assess the donor, and manage the patient through the transplant process and beyond. Dr. Chetan Kalal provides complete cirrhosis management at Gleneagles Hospital Mumbai — from diagnosis and cause identification through complication management, MELD-based transplant listing, LDLT evaluation, and post-transplant long-term care. Virtual consultations are available for patients from any Indian city or internationally. Frequently Asked Questions Can liver cirrhosis be reversed? Early-stage fibrosis (F1–F2) can regress with treatment of the underlying cause. Established cirrhosis (F4) does not reverse — but disease progression can be arrested, and with effective treatment of the cause (antiviral therapy for HBV/HCV, alcohol abstinence for ALD, weight loss for MASLD), patients can remain in compensated cirrhosis indefinitely. Decompensated cirrhosis requires specialist management and often transplant evaluation. Who is the best cirrhosis specialist in Mumbai? Dr. Chetan Kalal — DM (Hepatology), MD (Medicine), MRCP (UK), Associate Director Hepatology at Gleneagles Hospital Mumbai — manages the complete spectrum of cirrhosis from diagnosis through transplantation. He is the first DM Hepatologist of Maharashtra with 26+ PubMed publications and APASL-AARC consortium membership. What is the life expectancy with liver cirrhosis? Compensated cirrhosis: median survival >12 years with cause-specific treatment. Decompensated cirrhosis: median survival without transplant 1.8–3 years after first decompensation, depending on MELD score. Child-Pugh C without transplant: 1-year survival ~35–45%. These figures are averages — individual prognosis depends on cause, MELD score, complication control, and access to subspecialty care. Is liver transplant the only treatment for cirrhosis? No. Most cirrhosis patients do not need transplant. Treatment of the underlying cause, prevention of complications, and management of decompensation episodes can maintain
Liver Cirrhosis Specialist in Mumbai — Treatment, Complications & Transplant Read More »
Acute-on-Chronic Liver Failure (ACLF) is one of the most time-critical presentations in hepatology. In patients with chronic liver disease, an acute precipitant — infection, alcohol, viral hepatitis, drugs, or an unknown trigger — causes rapid deterioration with one or more organ failures. Without the right subspecialty input within the first 48–72 hours, mortality at 28 days can exceed 50% in Grade 3 ACLF. This article explains what ACLF is, how it is graded, what treatment looks like, and why subspecialty hepatologist input — not general physician or gastroenterology management — is essential. What is ACLF? ACLF is defined by the APASL (Asian Pacific Association for the Study of the Liver) as an acute hepatic insult manifesting as jaundice (serum bilirubin ≥5 mg/dL) and coagulopathy (INR ≥1.5) complicated within 4 weeks by clinical ascites and/or encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease. The APASL-AARC (ACLF Research Consortium) criteria, which Dr. Chetan Kalal has been directly involved in as part of AARC research, define three grades of ACLF based on the AARC score (0–15 points), which incorporates bilirubin, INR, creatinine, lactate, and hepatic encephalopathy grade. ACLF Grade 1 (AARC 5–7): 28-day mortality ~20–25% ACLF Grade 2 (AARC 8–10): 28-day mortality ~40–50% ACLF Grade 3 (AARC 11–15): 28-day mortality ~70–80% without transplant Dr. Chetan Kalal is a contributing member of the APASL-AARC consortium — the group that developed and validated the AARC score and ACLF grading system used across Asia. His clinical practice and research are centred on ACLF management, outcomes, and transplant decision-making in ACLF. Causes of ACLF — acute precipitants In India and Asia, the most common precipitants of ACLF are: Bacterial infection (30–40%) — including SBP, pneumonia, UTI, bacteraemia Alcohol — acute alcoholic hepatitis superimposed on alcoholic cirrhosis Hepatitis B reactivation (particularly in HBsAg-positive patients who are immunosuppressed) Superimposed acute viral hepatitis A or E Drug-induced liver injury (DILI/HILI) — including herbal and Ayurvedic preparations Gastrointestinal bleeding Unknown precipitant — approximately 20–30% of cases The underlying chronic liver disease is most commonly hepatitis B-related cirrhosis or alcoholic cirrhosis in the Indian population. ACLF management — what subspecialty hepatology delivers ACLF management requires rapid, coordinated, subspecialty-led care: 1. Precipitant identification and treatment Empirical antibiotics for presumed infection, early source control, antiviral therapy for HBV reactivation (tenofovir or entecavir, started within 24 hours), and removal of hepatotoxic drugs. Misidentifying or missing the precipitant leads directly to failure of recovery. 2. Organ support Renal replacement therapy for hepatorenal syndrome or intrinsic acute kidney injury. Vasopressors for septic shock. Ventilation for ACLF-related respiratory failure. Lactulose and rifaximin, terlipressin, and albumin infusions are the core medical armamentarium. 3. AARC score trajectory monitoring The direction of AARC score change over 3–7 days is more prognostically important than the admission score. A declining AARC score indicates potential recovery; a rising or plateau score at Grade 2–3 indicates that transplant candidacy assessment must be initiated without further delay. 4. Transplant candidacy assessment For ACLF Grade 2 and Grade 3, transplant candidacy should be evaluated in parallel with medical management — not sequentially. Patients with ACLF Grade 3 who are appropriate transplant candidates have significantly better outcomes with urgent LDLT. The window for successful transplantation in ACLF Grade 3 is narrow: approximately 7–14 days from peak deterioration. ACLF Grade 3 without transplant carries 70–80% 28-day mortality. With urgent LDLT in carefully selected patients, survival approaches 60–70% at 1 year. The decision to list for transplant in the context of acute deterioration requires experienced subspecialty hepatology judgment — not general physician assessment. Why a second opinion matters in ACLF ACLF is frequently mismanaged in non-subspecialty settings because: Transplant candidacy is not assessed at the right time — it is deferred until the patient is too sick to operate The AARC score trajectory is not monitored — the clinical team waits for “improvement” without a defined threshold for switching to transplant pathway Grade 3 ACLF is managed medically without ever reaching a transplant centre The precipitant is incompletely treated (e.g., antibiotics stopped too early, HBV reactivation missed) A subspecialty second opinion in ACLF — especially for Grade 2 or Grade 3 — can change the clinical trajectory. Dr. Kalal provides emergency ACLF second opinions, including virtual consultation for patients admitted elsewhere in India or internationally. ACLF and liver transplant — the India context India performs the majority of liver transplants in Asia as LDLT. For ACLF, LDLT has specific advantages over deceased donor transplantation: the timing can be controlled, and a healthy living donor liver is not subject to the ischaemic injury that deceased donor livers sustain. In well-selected ACLF patients, LDLT at an experienced Indian centre offers outcomes comparable to elective transplantation. Dr. Chetan Kalal provides the complete physician pathway for ACLF-to-transplant: diagnosis and grading, AARC score monitoring, organ support, listing decision, donor candidacy assessment coordination, and post-transplant aftercare. Frequently Asked Questions What is the survival rate for ACLF in India? Without liver transplant: Grade 1 ACLF has ~75–80% 28-day survival; Grade 2 approximately 50–60%; Grade 3 approximately 20–30%. With urgent LDLT in appropriate Grade 3 candidates at experienced centres, 1-year survival approaches 60–70%. Early subspecialty involvement significantly improves outcomes across all grades. Who is the best ACLF specialist in Mumbai? Dr. Chetan Kalal — DM (Hepatology), MD, MRCP (UK), First DM Hepatologist of Maharashtra — is an APASL-AARC consortium member and has published original research on ACLF outcomes and management. He practises at Gleneagles Hospital Mumbai with full LDLT capability. Can ACLF be treated without a liver transplant? Grade 1 and some Grade 2 ACLF can recover with aggressive medical management targeting the precipitant and supporting organ function. Grade 3 ACLF has extremely high mortality without transplantation. The key is early subspecialty assessment — not waiting to see if medical management will work before considering transplant. How is ACLF different from acute liver failure? Acute liver failure (ALF) occurs in a patient with no prior liver disease. ACLF occurs in a patient with pre-existing chronic liver disease. The management, prognosis, and transplant criteria
Best ACLF Specialist in Mumbai and India — Acute-on-Chronic Liver Failure Treatment Read More »
Dr. Chetan Kalal served as Organising Secretary of Grand Rounds in Hepatology 2026 — a Mid-Term Meeting of the Indian National Association for the Study of the Liver (INASL) — held 1st–3rd May 2026 at The St. Regis, Mumbai. Organising a national hepatology meeting is among the most demanding — and most significant — contributions a specialist can make to the medical community. The Organising Secretary is responsible for the scientific programme, faculty curation, session design, and the logistical execution of the entire conference. That Dr. Kalal chaired this role for the INASL Mid-Term Meeting reflects his standing at the centre of Indian hepatology — not on its periphery. Grand Rounds in Hepatology 2026 — Conference Overview Conference: Grand Rounds in Hepatology 2026 Type: Mid-Term Meeting of the Indian National Association for the Study of the Liver (INASL) Role: Organising Secretary — Dr. Chetan Kalal Dates: 1st–3rd May 2026 Venue: The St. Regis, Mumbai Theme: Clinical Dilemmas in Day-to-Day Hepatology Practice Organised by: Department of Hepatology About INASL — Indian National Association for the Study of the Liver INASL is India’s national hepatology society — the professional body for liver specialists across the country, affiliated with the International Association for the Study of the Liver (IASL). INASL organises the annual national conference (INASL Annual) and mid-term meetings that focus on specific clinical themes. The mid-term format typically concentrates on practical, case-driven, dilemma-based learning — the frontline clinical questions that the annual meeting cannot cover in depth. Being invited to organise an INASL Mid-Term Meeting — and specifically to chair its scientific structure as Organising Secretary — is one of the highest recognitions of expertise within the Indian hepatology community. Theme: Clinical Dilemmas in Day-to-Day Hepatology Practice The theme chosen for Grand Rounds in Hepatology 2026 is precisely what separates excellent hepatology from average hepatology: the dilemmas. Not the textbook cases with clear diagnoses and obvious treatment paths — but the real ones that arrive in clinic and in the emergency department: The cirrhotic patient with rising creatinine — HRS, pre-renal, intrinsic renal disease, or contrast nephropathy? The patient on immunosuppression with rising LFTs — rejection, CMV hepatitis, drug toxicity, or new autoimmune flare? The decompensated cirrhotic with ACLF Grade 2 — intensify medical management, list for transplant, or both simultaneously? The HCC nodule in a cirrhotic that doesn’t meet LI-RADS 5 criteria — biopsy, repeat imaging, or empirical treatment? The patient with AIH not responding to standard immunosuppression — inadequate dose, wrong diagnosis, or need for second-line therapy? Grand rounds as a format — real cases presented to a panel of experts for open discussion — is the oldest and most effective teaching method in clinical medicine. Applying it to hepatology at a national level, with curated clinical dilemmas drawn from daily practice across India, is exactly what the INASL Mid-Term format enables. The Organising Secretary shapes not just the logistics but the intellectual character of the meeting — which cases are presented, which faculty are invited to comment, which controversies are surfaced and debated. This is academic leadership, not administrative support. The St. Regis, Mumbai — Scientific Meeting at India’s Premier Venue The St. Regis Mumbai is among the most prestigious meeting venues in India — its selection reflects the calibre of the conference and the national importance of the INASL Mid-Term Meeting. Mumbai as the host city is significant: the financial capital of India, home to the highest concentration of private tertiary liver care centres in the country, and a hub for both domestic and international hepatology expertise. Dr. Chetan Kalal — Academic Leadership in Indian Hepatology The Grand Rounds in Hepatology 2026 Organising Secretary role represents the latest in a sustained record of academic leadership: Organising Secretary, Grand Rounds in Hepatology 2026 — INASL Mid-Term Meeting, The St. Regis Mumbai, 1–3 May 2026 Invited Faculty, LTSICON 2026 Midterm — Liver Transplant Society of India Conference, Pune — Case-Based Panel Discussion: Viral and Invasive Fungal Infection: Cause and Effect Relationship with Graft Dysfunction Invited Faculty, DRILLS 2026 — Decisions Reasoning Innovations & Learning in Liver DiseaseS, 7th Edition — ILBS, Pullman Aerocity, New Delhi, 13–14 June 2026 Invited Faculty, CRITICON 2026 — National Critical Care Conference Invited Faculty, LIVERCON 2026 — National Hepatology Conference APASL-AARC Consortium Member — contributing to ACLF criteria development and validation AASLD Foundation Young Investigator Award — 2016 and 2017 Fellow, National Academy of Medical Sciences (FNAMS) — 2022–23 Across 2026 alone, Dr. Kalal has been an organiser of one national meeting and faculty at four separate national and subspecialty conferences — a record of sustained engagement with the hepatology academic community that places him at its leadership tier. Clinical Dilemmas in Hepatology — Selected Topics The theme of Grand Rounds in Hepatology 2026 — clinical dilemmas in daily practice — maps directly onto Dr. Kalal’s clinical and research interests. Areas where dilemma-based hepatology teaching is most impactful include: ACLF: to transplant or not, and when ACLF Grade 2 and 3 present the most acute clinical dilemmas in hepatology. The window for successful LDLT in Grade 3 ACLF is 7–14 days — too early and the patient may recover medically; too late and operative risk becomes prohibitive. The decision requires real-time synthesis of AARC score trajectory, organ failure profile, donor availability, and patient and family readiness. No algorithm replaces experienced clinical judgment at this intersection. Antibiotics in cirrhosis — when, which, and how long Antibiotic stewardship in cirrhotic patients is a dilemma: these patients are highly susceptible to bacterial infections (which are the most common ACLF precipitant), but antibiotic overuse drives multi-drug resistant organism (MDRO) infections that are increasingly untreatable. The balance between empirical broad-spectrum coverage and judicious de-escalation guided by cultures is a daily clinical challenge in any busy liver unit. Renal function in cirrhosis — the creatinine trap Serum creatinine systematically underestimates the degree of renal impairment in cirrhotic patients because of reduced muscle mass (sarcopenia) and decreased hepatic creatinine production. A cirrhotic with creatinine 1.0 mg/dL may have a GFR
Dr. Chetan Kalal has been invited as Faculty to the LTSICON 2026 Midterm Conference in Pune, where he will lead a Case-Based Panel Discussion on Viral and Invasive Fungal Infection: Cause and Effect Relationship with Graft Dysfunction — one of the most complex and clinically consequential topics in post-liver transplant medicine. LTSICON (Liver Transplant Society of India Conference) is India’s premier liver transplantation conference, convening the country’s leading transplant surgeons, hepatologists, intensivists, and allied specialists. Invitation as faculty to a case-based panel discussion represents the highest tier of participation — it is a recognition of subspecialty depth, not just attendance. About LTSICON 2026 — Midterm, Pune The Liver Transplant Society of India (LTSI) organises both an annual conference and a midterm conference, with rotating national venues. The midterm format typically focuses on intensive clinical learning — case-based discussions, controversial topics, and subspecialty deep-dives that the larger annual meeting cannot accommodate in the same depth. The case-based panel discussion format places real, de-identified transplant cases before a panel of experts who debate diagnosis, management decisions, and outcomes in real time — the most intellectually demanding and educationally effective format in post-graduate medical education. Dr. Kalal’s invitation to faculty this session reflects his standing as one of India’s authoritative voices on post-transplant infectious complications and graft dysfunction — a domain that sits at the intersection of transplant hepatology, infectious disease, and critical care. The clinical topic: Viral and Invasive Fungal Infection — Cause and Effect with Graft Dysfunction Post-liver transplant infections are the leading cause of morbidity and mortality in the first year after transplantation. The relationship between infection and graft dysfunction is bidirectional and frequently misunderstood in non-specialist settings: infections cause graft dysfunction, and graft dysfunction predisposes to infections. Untangling this relationship determines whether a deteriorating graft is rejected, infected, or both — and the treatment is fundamentally different for each. Viral infections and graft dysfunction — the CMV problem Cytomegalovirus (CMV) is the most clinically significant viral pathogen after liver transplantation. It causes two distinct problems: Direct CMV disease: CMV hepatitis (the graft itself is the target — rising LFTs, histology showing cytomegalic inclusions), CMV colitis, CMV pneumonitis. In the graft, CMV hepatitis causes a pattern of liver dysfunction that mimics rejection on biochemistry — the distinction requires liver biopsy with immunohistochemistry. Indirect CMV effects: CMV is immunomodulatory — it broadly suppresses immune function, increasing susceptibility to other opportunistic infections (bacterial, fungal, other viral). CMV-seropositive recipients receiving organs from CMV-seropositive donors (D+/R+) are at highest risk of clinically significant disease. Standard prophylaxis: valganciclovir for 3–6 months post-transplant in high-risk patients. Breakthrough CMV despite prophylaxis, or CMV disease in a patient on prophylaxis, requires intravenous ganciclovir and resistance testing. Ganciclovir-resistant CMV (UL97 and UL54 mutations) is an emerging problem requiring foscarnet — a nephrotoxic agent — creating a management dilemma in patients already receiving calcineurin inhibitors. Epstein-Barr Virus (EBV) and PTLD EBV causes post-transplant lymphoproliferative disorder (PTLD) — a spectrum from infectious mononucleosis-like illness to aggressive B-cell lymphoma. PTLD is the most feared late viral complication of immunosuppression. EBV viral load monitoring (quantitative PCR) is mandatory in EBV-seronegative recipients (R-) receiving organs from EBV-positive donors (D+) — the highest-risk combination, common in paediatric transplantation. Graft dysfunction in PTLD can occur via hepatic PTLD (infiltration of the liver graft by lymphoproliferative cells) or via systemic disease with secondary hepatic involvement. The key clinical challenge is distinguishing PTLD from rejection on liver biopsy — both can cause portal inflammation and bile duct injury. Other viral pathogens Hepatitis B recurrence: HBV recurrence in the graft after liver transplantation for HBV-related cirrhosis — prevented with lifelong antiviral therapy (tenofovir or entecavir) plus hepatitis B immunoglobulin (HBIG) in the perioperative period. Fibrosing cholestatic hepatitis B (FCH-B) is a devastating form of graft HBV recurrence with rapid progression to graft failure. HCV recurrence: Now effectively treated with direct-acting antivirals (DAAs) post-transplant; fibrosing cholestatic hepatitis C (FCH-C) is rare with current prophylaxis and early treatment. Adenovirus, HHV-6, parvovirus B19: Less common but clinically significant in immunosuppressed recipients; may cause hepatitis, bone marrow suppression, or encephalitis depending on the pathogen. Invasive fungal infections — the underestimated threat Invasive fungal infections (IFIs) after liver transplantation carry mortality rates of 50–90% for invasive aspergillosis and 30–50% for invasive candidiasis, even with optimal antifungal therapy. They occur predominantly in the first 30–90 days post-transplant, when immunosuppression is most intense and surgical trauma to the biliary tree and vasculature creates entry points. Invasive candidiasis (Candida albicans, Candida glabrata, Candida krusei) is the most common IFI in liver transplant recipients. Risk factors: prolonged surgery, Roux-en-Y biliary reconstruction, renal replacement therapy, re-transplantation, high intraoperative transfusion requirements. Treatment: echinocandins (caspofungin, micafungin) first-line; azoles for step-down. Candida glabrata and krusei have intrinsic azole resistance — species identification and sensitivity testing are essential. Invasive aspergillosis (Aspergillus fumigatus predominantly) — the most lethal IFI post-transplant. Pulmonary aspergillosis presenting as cavitating lung lesions in a recipient on high-dose steroids (e.g., post-rejection treatment) is classic. CT chest showing “halo sign” — a nodule surrounded by ground-glass opacity — is the hallmark finding. Treatment: voriconazole first-line; isavuconazole as alternative. Critical interaction: voriconazole is a potent CYP3A4 inhibitor that dramatically increases tacrolimus levels — dose reduction of tacrolimus by 50–75% required immediately on initiation, with twice-weekly tacrolimus monitoring until stable. Mucormycosis — rare but increasingly reported post-transplant, particularly in diabetic recipients or those receiving high steroid doses. Angio-invasive, rapidly fatal without surgical debridement plus liposomal amphotericin B. COVID-19-associated mucormycosis (CAM) was disproportionately reported in India in 2021 in immunosuppressed patients, including transplant recipients. Pneumocystis jirovecii pneumonia (PJP) — prevented with trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis for the first 6–12 months post-transplant. Breakthrough PJP in a recipient on prophylaxis suggests compliance failure, drug interaction, or unusually intense immunosuppression. The cause-and-effect relationship with graft dysfunction This is the crux of Dr. Kalal’s panel discussion — and the area where clinical errors most commonly occur: Infection causing graft dysfunction: CMV hepatitis raises LFTs and bilirubin, mimicking rejection. Fungal cholangitis (Candida in the biliary tree post-Roux-en-Y reconstruction) causes
Finding the right hepatologist in Mumbai or India is not straightforward. The category is loosely used — “liver specialist” can mean a gastroenterologist with a liver interest, a general physician managing hepatitis, or a fully trained DM Hepatologist with dedicated subspecialty experience in transplantation, ACLF, and complex liver disease. The difference matters significantly when the diagnosis is serious. This article clarifies what to look for, who qualifies as India’s best hepatologist, and how to access the right expertise whether you are in Mumbai, another Indian city, or abroad. What makes someone India’s best hepatologist? The term is used widely and verified rarely. The meaningful criteria are: Qualification: DM (Hepatology) — India’s highest subspecialty degree in liver disease, awarded after a three-year dedicated training program beyond MD. Distinct from DM Gastroenterology and from MD/DNB with a liver interest. Transplant experience: Direct involvement in liver transplant evaluation, MELD-based listing, LDLT (living donor liver transplant) candidacy assessment, and post-transplant aftercare — not merely referral to a surgical team. Critical care exposure: Direct management of ACLF, acute liver failure, variceal bleeding, SBP, HRS, and hepatic encephalopathy in an inpatient and ICU setting. Research and publication: Peer-reviewed output in hepatology — not padded citation counts but original clinical research, preferably indexed in PubMed with multi-centre or guideline-level impact. International recognition: Membership of EASL, AASLD, APASL, and recognition via fellowship, award, or faculty invitation from these bodies. Dr. Chetan Kalal holds DM (Hepatology), MD (Medicine), and MRCP (UK). He is the first DM-qualified Hepatologist in Maharashtra, Associate Director of Hepatology & Transplant Medicine at Gleneagles Hospital Mumbai, and has 26+ PubMed-indexed publications. He has been recognised with the AASLD Foundation Award and serves as faculty at national and international hepatology conferences. Best hepatologist in Mumbai — what the title should mean Mumbai has multiple hospitals offering hepatology services. The distinction between a good hepatologist and the best hepatologist in Mumbai comes down to: Subspecialty DM training (not just a gastroenterologist who sees liver cases) Active liver transplant programme involvement — including LDLT, which is the dominant modality in India Management of high-acuity presentations: ACLF grade 3, acute liver failure, refractory ascites, multi-organ dysfunction Availability for second opinions, structured virtual consultations, and NRI care coordination Dr. Chetan Kalal practises at Gleneagles Hospital Mumbai as Associate Director, with additional consultant appointments at Breach Candy Hospital, Khar Hinduja Hospital, and Saifee Hospital — covering South Mumbai, Khar, and the broader city geography. Best liver transplant specialist in Mumbai Liver transplantation in India is primarily living donor liver transplantation (LDLT) — a technically demanding modality where a lobe of the liver from a healthy living donor is transplanted into the recipient. The hepatologist’s role in a transplant programme is distinct from the surgeon’s: Pre-transplant: Establishing transplant candidacy, MELD scoring, listing decisions, managing the patient while awaiting transplant, bridging therapies for HCC Donor evaluation: Medical assessment of the living donor — ruling out contraindications, ensuring donor safety Post-transplant: Immunosuppression management (tacrolimus, mycophenolate, steroids), rejection surveillance, CMV/EBV monitoring, long-term graft health, managing metabolic complications after transplant A liver transplant specialist in Mumbai who is also a DM Hepatologist provides integrated pre- and post-transplant medical care — the physician-side of the transplant, not just the surgical procedure. Dr. Chetan Kalal provides complete liver transplant physician care: pre-transplant candidacy evaluation, MELD-based listing, LDLT donor assessment coordination, and comprehensive post-transplant medical aftercare including immunosuppression, graft monitoring, and long-term follow-up. He practises at Gleneagles Hospital Mumbai. Best hepatologist in India — national perspective India has a small number of DM-qualified hepatologists distributed across major cities — primarily Mumbai, Delhi, Chennai, Hyderabad, Kolkata, and Ahmedabad. The concentration is highest in tertiary liver centres attached to major hospitals or medical institutes (ILBS Delhi, PGIMER Chandigarh, CMC Vellore, AIIMS, and select private hospitals). For patients from any Indian city seeking subspecialty hepatology review: In person — Mumbai: Gleneagles Hospital Mumbai is accessible from all major Indian cities via direct flight. South Mumbai location (Breach Candy) is also available. Virtual consultation: A full structured hepatology consultation — review of all records, video call, written clinical summary — is available from any location in India without travel to Mumbai. Conditions for which all-India patients most commonly seek Dr. Kalal’s opinion: ACLF (second opinion on grade, management, and transplant candidacy), autoimmune hepatitis (diagnosis confirmation, treatment adequacy), Wilson’s disease, HCC staging, post-transplant complications, and decompensated cirrhosis with unclear aetiology. Best liver transplant specialist in India India performs among the highest volumes of LDLT globally, concentrated in Mumbai, Delhi, and Chennai. The best liver transplant specialist in India is one who combines: DM Hepatology training with direct transplant programme integration High-volume LDLT experience — both evaluation and post-transplant management Familiarity with MELD 3.0, current EASL and APASL transplant criteria, and ACLF-to-transplant pathways Ability to manage complex post-transplant scenarios: calcineurin inhibitor toxicity, de novo autoimmune hepatitis post-transplant, recurrent HCV/HBV in graft, metabolic syndrome after transplant For NRI patients who received a liver transplant in India and subsequently relocated abroad — to the UK, USA, UAE, Singapore, or Australia — ongoing post-transplant hepatology follow-up with Dr. Kalal is available via structured virtual consultation, coordinated with local treating physicians. Conditions treated — complete list Liver cirrhosis — alcoholic, viral (HBV, HCV), autoimmune, metabolic (MASLD/NASH), cryptogenic Acute-on-chronic liver failure (ACLF) — all grades per APASL-AARC criteria Acute liver failure (ALF) — all aetiologies including drug-induced, viral, Wilson’s Hepatitis B — chronic HBV, HBV reactivation, HBV-related cirrhosis and HCC Hepatitis C — DAA therapy, retreatment, post-SVR surveillance Autoimmune hepatitis (AIH) — diagnosis, treatment, overlap syndromes Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) Wilson’s disease and hereditary haemochromatosis MASLD / NAFLD / NASH — metabolic fatty liver disease Drug-induced liver injury (DILI) and herb-induced liver injury (HILI) Hepatocellular carcinoma (HCC) — surveillance, staging, locoregional therapy, transplant assessment Variceal bleeding, ascites, spontaneous bacterial peritonitis (SBP) Hepatic encephalopathy and hepatorenal syndrome (HRS) Portal hypertension and Budd-Chiari syndrome Liver transplant evaluation, LDLT candidacy, post-transplant aftercare Where to see Dr. Chetan Kalal in Mumbai Primary hospital: Gleneagles Hospital Mumbai — Associate
Best Hepatologist and Liver Transplant Specialist in Mumbai and India — Dr. Chetan Kalal Read More »
Most patients who come to me have already seen a doctor. Some have seen several. What brings them to a subspecialty hepatologist is usually not the absence of a diagnosis — it’s the absence of a clear path forward. This article explains what a subspecialty hepatology consultation actually involves, how it differs from a general gastroenterology review, and what patients — in Mumbai, across India, and internationally — should expect when they book with me. What is a DM Hepatologist and why does it matter? In India, the highest postgraduate qualification in hepatology is the DM (Doctorate of Medicine) in Hepatology — a three-year subspecialty training program following an MD, focused exclusively on liver and biliary diseases, liver transplantation, and advanced hepatological management. It is distinct from a DM Gastroenterology and from an MD Medicine or MD Gastroenterology. I am the first DM-qualified Hepatologist in Maharashtra — a distinction that reflects both the timing of the qualification pathway’s establishment in India and the depth of subspecialty training it requires. The practical difference for patients: a DM Hepatologist has trained specifically in the full spectrum of liver disease management — from acute liver failure requiring ICU-level interventions to complex autoimmune liver diseases, hepatocellular carcinoma staging, and liver transplant evaluation. This is not generalist gastroenterology with a liver interest. It is a distinct subspecialty. A DM Hepatologist in India holds the Doctorate of Medicine in Hepatology — the country’s highest subspecialty qualification in liver disease — following a dedicated three-year training program beyond an MD degree. Dr. Chetan Kalal is the first DM Hepatologist in Maharashtra, practising at Gleneagles Hospital Mumbai with additional affiliations at Breach Candy, Khar Hinduja, and Saifee Hospitals. What conditions does Dr. Chetan Kalal treat? My practice covers the complete spectrum of adult liver disease: Chronic liver disease and cirrhosis Liver cirrhosis (all causes — alcoholic, viral, autoimmune, metabolic), NAFLD/MAFLD (non-alcoholic/metabolic fatty liver disease), autoimmune hepatitis, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), Wilson’s disease, hereditary haemochromatosis, alpha-1 antitrypsin deficiency, and drug-induced liver injury (DILI). Viral hepatitis Chronic hepatitis B — including antiviral therapy initiation, monitoring, and management of HBV-associated cirrhosis and HCC. Chronic hepatitis C — direct-acting antiviral (DAA) therapy, retreatment for prior failures, and post-SVR surveillance. Acute and critical liver disease Acute liver failure (ALF), acute-on-chronic liver failure (ACLF — all grades including grade 3), variceal bleeding, spontaneous bacterial peritonitis (SBP), hepatic encephalopathy, hepatorenal syndrome (HRS), and ascites management. Liver cancer Hepatocellular carcinoma (HCC) — surveillance in at-risk patients, BCLC staging, locoregional therapy coordination (TACE, ablation), Milan criteria assessment for transplant, and sorafenib/systemic therapy for advanced disease. Liver transplantation Pre-transplant evaluation, MELD scoring, living donor liver transplant (LDLT) candidacy assessment, donor evaluation coordination, and post-transplant aftercare including immunosuppression management, rejection surveillance, and long-term graft health. Rare and complex hepatological disorders Budd-Chiari syndrome, portal vein thrombosis, cholestatic liver diseases, metabolic liver diseases, and overlap syndromes. IPD (Inpatient) Hepatology — Advanced Acute Care For patients admitted to hospital with acute liver presentations, the involvement of a DM Hepatologist in inpatient (IPD) management is not standard everywhere in India — many acute liver cases are managed by general physicians or gastroenterologists without hepatology subspecialty training. In my IPD practice, the clinical focus is on: ACLF management — grading, organ support, and rapid transplant candidacy assessment where indicated Variceal bleeding — endoscopic management coordination, pharmacological secondary prophylaxis, TIPS assessment SBP and HRS — early identification, aggressive fluid management, terlipressin protocols, renal replacement decisions Hepatic encephalopathy — precipitant identification, lactulose/rifaximin protocols, minimal hepatic encephalopathy assessment Acute liver failure — King’s College Criteria assessment, transplant listing urgency evaluation, intensive monitoring The distinction between a gastroenterologist managing an acute liver patient and a DM Hepatologist leading that care is most visible — and most consequential — in these acute presentations. Expert Second Opinion — What it actually means A second opinion in liver disease is one of the most overused and least meaningfully delivered services in Indian healthcare. Here is what it should deliver: What a genuine subspecialty second opinion includes Independent diagnosis verification — not acceptance of the prior diagnosis, but an independent assessment: does the histopathology actually support the stated diagnosis? Does the imaging pattern match? Are the labs consistent with the proposed aetiology? Treatment gap identification — is the current treatment aligned with current international guidelines (EASL 2024, AASLD guidelines)? Are there evidence-based options not being utilised? Is the immunosuppression dose appropriate? Transplant candidacy assessment, if relevant — for any patient with decompensated cirrhosis or ACLF, the question “should transplant be on the table?” should be explicitly answered, not deferred until crisis point. Written structured output — a clinical direction report: confirmed or revised diagnosis, clear rationale, optimal treatment pathway, and defined next steps. Not a letter of endorsement. Not “continue current management.” A genuine liver disease second opinion involves independent re-evaluation of histopathology, imaging, and laboratory data — not confirmation of the existing diagnosis. Dr. Chetan Kalal’s second opinion service delivers a written clinical direction report: revised or confirmed diagnosis with rationale, treatment pathway, and transplant candidacy assessment where applicable. Available in-person in Mumbai and via virtual consultation for patients in USA, UK, UAE, Singapore, Australia, Canada, New Zealand, and across Asia and the Middle East. Who needs a second opinion? A structured subspecialty second opinion is warranted when: You have been diagnosed with cirrhosis or advanced fibrosis and are unclear about the cause, stage, or prognosis Your liver biopsy result has been interpreted without subspecialty hepatology review You have been told you are “not a liver transplant candidate” — particularly if this was determined without applying current ACLF candidacy criteria or by a non-transplant specialist Your current treatment (for hepatitis B, autoimmune hepatitis, PBC, PSC, or NAFLD) does not appear to be working and no explanation has been offered HCC (liver cancer) has been found and you want independent staging confirmation before committing to a treatment pathway You are an NRI patient whose family member in India has received a complex liver diagnosis and you want
The 2024 EASL liver transplant guidelines are the first full revision since 2016. Dr. Chetan Kalal explains what actually changed for Indian patients: ACLF candidacy, expanded indications, MELD 3.0, and why most global updates miss the point for an LDLT-dominant system.
Liver Transplant Guidelines 2026 — What Actually Changed for Indian Patients Read More »
Dr Chetan Kalal shares his clinical perspective on managing ACLF in Mumbai — how to diagnose it correctly, what changes outcomes, and when to refer for transplant evaluation.
Managing Acute-on-Chronic Liver Failure: A Clinical Perspective from Mumbai Read More »
Expert liver transplant care in India by Dr. Chetan Kalal, Associate Director – Hepatology, Gleneagles Hospital Mumbai. Evaluation, MELD scoring, donor options, costs, and outcomes explained.
Liver Transplant in India: What You Need to Know | Dr. Chetan Kalal Read More »
